Understanding how bacteria respond to a new antimicrobial called AGXX
Elucidating bacterial responses to the novel antimicrobial AGXX
This study is looking at a new treatment called AGXX that might help fight tough infections caused by bacteria like Pseudomonas aeruginosa, which can be a problem for people with cystic fibrosis and burn injuries, to see if it can be a better option when antibiotics don’t work.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Illinois State University NIH-funded |
| Lab location | 1 site (Normal, United States) |
| Project ID | NIH-10877000 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a novel antimicrobial compound, AGXX, against drug-resistant bacteria, particularly Pseudomonas aeruginosa, which is a common infection in cystic fibrosis patients and burn victims. The study focuses on how AGXX, which contains silver and ruthenium, kills bacteria by generating reactive oxygen species. Researchers will analyze the bacterial responses to AGXX exposure to determine its potential as a treatment option. The goal is to find alternative strategies to combat antibiotic resistance and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with cystic fibrosis or burn wounds who are at risk of infections from Pseudomonas aeruginosa.
Not a fit: Patients with infections caused by bacteria other than Pseudomonas aeruginosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Previous research has shown promise in using silver-containing compounds for treating bacterial infections, indicating potential success for this novel approach.
Where this research is happening
Normal, United States
- Illinois State University — Normal, United States (Active)
Researchers
- Principal investigator: Dahl, Jan-Ulrik — Illinois State University
- Study coordinator: Dahl, Jan-Ulrik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.